Background: Cranial radiation therapy (CRT) is required for successful treatment of a variety of brain tumours in childhood. Objective: To investigate whether childhood CRT leads to altered sleep -wakefulness organization in adulthood, and to identify the determinants of such alterations. Subjects and methods: Subjective (questionnaires) and objective (actigraphy) measures of circadian rhythmicity and sleep were assessed in 25 individuals, 8-29 years after CRT for medulloblastoma (n ¼ 17) or other intracranial tumours (n ¼ 8), and in a group of 34 age-matched healthy individuals. Serum GH peak during insulin-induced hypoglycaemia and serum concentrations of prolactin and leptin (expressed per fat mass) were determined in the CRT group. Results: The CRT group showed a markedly increased sleep duration (8.66 h, compared with 7.66 h in controls). In addition, the sleep -wake rhythm showed greater amplitude and less fragmentation, and less tolerance for alterations in the timing of sleep. Regression analysis showed both radiation dosage and neuroendocrine status to be determinants of sleep changes, suggesting that some of the alterations may be normalized with hormone supplementation.
Introduction
Cranial radiation therapy (CRT) is required for successful treatment of a variety of brain tumours in childhood. Combinations of surgery, chemotherapy and CRT have improved the survival rate of children suffering from brain tumours, and as a result the late sequelae of the treatment have become apparent. In adults who have been disease-free for many years, these sequelae involve radiation-induced alterations in the hypothalamo -pituitary axis, and the hypothalamus is generally recognized as the more radiation-sensitive structure (1 -4) . These neuroendocrine alterations cannot be attributed to the location of the tumour or the surgical procedures, and they do not appear to be related to the presence or absence of chemotherapy (5, 6) .
No systematic studies of the long-term sequelae of CRT for sleep regulation have been reported, although the role of the hypothalamus in sleep regulation is well established [for reviews see (7, 8) ]. Although data on sleep -wake rhythms in disease-free individuals who have been treated succesfully during childhood are not available, signs of short-term disturbances of sleepwakefulness regulation in children after CRT have been reported. Sleepiness is the core symptom of the somnolence syndrome that is transiently present in about 60% of children 4 -6 weeks after completion of CRT (9) . Fagioli et al. (10) performed a study of sleep patterns in children who had been treated with CRT 1-7 years previously, and found a normal amount and distribution of sleep stages in spite of decreased growth hormone (GH) reserve.
The aim of our study was to investigate the long-term effects of CRT on sleep in adulthood. Sleep-wakefulness sequelae in the longer term may be clinically relevant, given the strong impact that a disturbed sleep -wake rhythm may have on the quality of life. We included assessment of GH status, prolactin (PRL), and leptin expressed per kg body fat mass (Leptin/FM), because a close association of these neuroendocrine parameters with the sleep -wake rhythm has been demonstrated (11 -14) . In addition, GH deficiency, hyperprolactinaemia and increased leptin concentrations have been reported in some patients treated with CRT (2, 3, 15, 16) . In order to gain insight into possible determinants of sleep changes, we performed stepwise regression analyses, with neuroendocrine status, radiation dose, chemotherapy, age at treatment and post-treatment interval as candidates.
Participants and methods

Participants
The study was performed in two groups of individuals, a CRT group and a control group.
The CRT group consisted of 25 individuals (11 women and 14 men) treated with CRT for intracranial tumours during childhood at the Emma Kinderziekenhuis (Academic Medical Centre, Amsterdam, The Netherlands). Individuals were eligible if they had ceased treatment more than 5 years previously and were older than 18 years at the time of the present investigation. Exclusion criteria for the insulin tolerance test were recent seizures and symptomatic ischaemic heart disease. The study procedure was approved by the Medical Ethics Committee of the Academic Medical Centre of the University of Amsterdam (Amsterdam, The Netherlands). Written informed consent was obtained from all participants.
Clinical and endocrine data of the CRT group are summarized in Table 1 . In all of them (11 women and 14 men, ages 25.6^4.8 years; mean^S.D.), a complete medical history and physical examination were performed. All were postpubertal (Tanner stage V). The median age at diagnosis was 9 years (range 4-19 years). The median interval between cessation of treatment and investigation was 16 years (range 8-29 years). After surgery, all members of the group had been treated with CRT, with a mean dose to the cranium of 40.3^10.1 Gy (mean^S.D.) and most (n ¼ 22) received an additional boost, presumably not including the hypothalamic-pituitary region (5), of 16.2^7.3 Gy (mean^S.D.), with the possible exception of minor scatter irradiation. Thirteen individuals had received additional chemotherapy. Two of the group were receiving replacement therapy with levothyroxine for hypothyroidism and one was receiving 1-desamino-8-D-AVP for partial central diabetes insipidus. None of the patients suffered from central adrenal insufficiency, and none had previously been treated for GH deficiency at the time of investigation.
The control group consisted of 34 volunteers in self-reported general good health, who were recruited through advertising and among siblings, students, residents and staff of our institutes. We included 19 women and 15 men (age 26.7^3.6 years; mean^S.D.); these numbers did not differ significantly from those in the CRT group with respect to the proportion of women and men (x 2 ¼ 0.81, df ¼ 1, P ¼ 0.37). Sleep and circadian rhythmicity were studied in the same way and in the same period as in the CRT group, as described below. The CRT and control groups were comparable with respect to socioeconomic obligations. The majority of both patients and controls had jobs with fixed schedules and lived alone or with a partner, occasionally with their parents. In the control group, 22 were in employment, seven were unemployed and five were students. In the CRT group, 15 had jobs (some part-time or in sheltered employment, or both), five were students and five were unemployed. Thus, in both groups, the majority of members led a time-structured life and the groups were fully matched with respect to employment (
Assessment of hormones and body composition in the CRT group Body composition was measured by bioelectrical impedance analysis using the Holtain Body Composition Analyser (Holtain Limited, Crosswell, Dyfed, UK). Bioelectrical impedance analysis results were not available for one individual. The serum concentration of leptin was measured by RIA (Linco Research, St Charles, MO, USA) with a limit of detection of 0.5 ng/ml serum, a linear standard curve up to 100 ng/ml and an intraassay variation ranging from 3.4 to 8.3% (17) . PRL was measured by a solid-phase, two-site, time-resolved fluoroimmunometric assay (Delfia Prolactin, Wallac Oy, Turku, Finland) with a limit of detection of 1.0 mg/l. The intra-assay coefficient of variation (CV) was 4 -6% (5 -24 mg/l) and the interassay CV was 5.5 -7.2% (4 -50 mg/l), with reference values for plasma PRL of 4.0 -25 mg/l in women and 0.5 -19.0 mg/l in men (18) . An insulin tolerance test in the postabsorptive state had been performed as part of a previous study (6) . Briefly, blood samples were drawn to determine GH and cortisol 30 and 15 min before and 15, 30, 45, 60, 90 and 120 min after an intravenous injection of 0.15 U insulin/kg body weight (Actrapid, Novo Nordisk, Bagsvaerd, Denmark). GH was measured by immunoradiometric assay (Nichols Institute Diagnostics, San Juan Capistrano, CA, USA).
A peak plasma GH concentration of . 18.9 mU/l was considered a normal response. An absolute GH deficiency was defined as a GH response , 6.75 mU/l and an insufficient response as between 6.75 and 18.9 mU/l (6). All assessments commenced at 09:00 h. No participant showed central adrenal insufficiency as apparent from a normal cortisol response during insulin-induced hypoglycaemia (cortisol peak . 550 nmol/l, or absolute increase in plasma cortisol . 280 nmol/l during hypoglycaemia).
Assessment of sleep and circadian rhythm
Objective and subjective measures of sleep and circadian rhythms were investigated in both groups. Actigraphy (Actiwatch, Cambridge Neurotechnology, Cambridge, Cambs, UK) was used to assess objective measures for Astro, astrocytoma; cranio, craniopharyngioma; epen, ependymoma; GH peak, peak serum GH response to insulin-induced hypoglycaemia; Leptin/FM, serum leptin expressed per kg fat mass; med, medulloblastoma; nasoph, nasopharynx carcinoma; nd, not determined; OC, oral contraceptive; path inconcl, pathology inconclusive; T, thyroxine; VP, vasopressin.
circadian and sleep behaviour. Actigraphs are small, lightweight, wrist-worn solid-state recorders that record movement-induced accelerations. In long-term recordings, the level of activity shows a circadian pattern that can be quantified (19) , and indices of sleep quality can be estimated from the nocturnal levels and patterns of activity. The patterning of periods of rest and activity is highly correlated with, but not identical to, periods of sleep and wakefulness, and will be referred to as 'sleep -wake rhythm' throughout this paper. Participants were asked to wear the actigraph continuously for 1 week, and to indicate bedtimes and rise-times, both by pushing a marker button on the Actiwatch and by keeping a sleep -wake log. The usefulness of actigraphy for investigating circadian rhythm (19) and sleep (20) disturbances has been demonstrated. SleepWatch software (Cambridge Neurotechnology), which compares favourably with other such packages (21), was used for estimation of the following objective sleep and circadian variables from the actigraphic recordings:
(1) The duration of the sleep period, which is the time from sleep onset to final awakening. (2) The percentage of time actually asleep during this period -that is, the duration of the sleep period minus intervening awakenings. We preferred this variable to the closely related 'sleep efficiency', as it excludes the period of wakefulness between lights out and sleep onset (sleep latency), which is extremely sensitive to small deviations from the exact time of lights out in the sleep diaries. (3) The mean duration of the sleep bout. This variable gives an impression of the structure of sleep. Sleep is not one continuous process from bedtime to wake-up time, but is interrupted by short awakenings that may or may not be perceived consciously. The mean sleep bout duration measures the average duration of uninterrupted sleep between two consecutive awakenings. Sleep bouts of long duration are related to a high sleep efficiency, the occurrence of 'deep' (i.e. slow-wave) sleep, and are negatively related to nocturnal awakenings (22, 23) . (4) The intradaily stability, quantifying the strength of coupling of the sleep-wake rhythm to the 24-h regularity in the environment (19) . A low intradaily stability is indicative of a weak circadian rhythm. (5) The intradaily variability, quantifying the fragmentation of periods of rest and activity (19) . A high intradaily variability is indicative of many transitions between periods of rest and activity, as opposed to one sustained period of activity during the day and one sustained period of rest during the night.
(6) The relative amplitude, quantifying the difference between daytime and night-time activity levels (19) . A low relative amplitude is also indicative of a weak circadian rhythm.
Four questionnaires for evaluation of subjective sleep and circadian behaviour were used in order to evaluate the general occurrence of disturbed sleep, the ability to overcome drowsiness, the flexibility of sleep -wake rhythm habits and the morning/eveningness:
(1) The Pittsburgh Sleep Quality Index (PSQI) (24) , to determine subjective sleep quality and disturbances. Habitual bedtime and rise-time are also obtained from the PSQI. (2) The languidity scale of the Circadian Type Inventory (CTI) (25) , to assess the difficulty in overcoming drowsiness (CTI-languidity). (3) The flexibility scale of the Circadian Type Inventory (CTI) (25) , to assess the tolerance and habits concerning flexible sleep times (CTI-flexibility). (4) The Composite Morningness Questionnaire (CMQ) (25) , to assess morning or evening 'type' -that is, preferences associated with morning or evening activity.
Statistical methods
Group differences in the sleep and circadian rhythm variables were evaluated using Mann -Whitney tests at a significance level of 0.05. The sample size allowed the detection of medium to large group differences with a statistical power of 0.79 at a significance level of 0.05. Within the CRT group, stepwise regression analyses were performed in order to determine how sleep-wake rhythm variables were related to endocrine status (GH, PRL, leptin/FM), total dose of radiation (Gy), chemotherapy, age at treatment and post-treatment interval. Variables were log-transformed in case of deviation from a normal distribution (ShapiroWilk test). In addition, sex was introduced as a variable, because of sex differences in serum PRL and leptin concentrations (26) . Given the large number of possible predictors as compared with the number of observations, stability of the regression results was verified by randomly excluding observations; only stable results are reported. In the regression steps, the critical F-values were set at 4.25, corresponding to a significance level of 0.05 for any single test (27) . Spearman's rho was calculated in order to investigate correlations between GH, PRL and leptin (leptin/FM).
Results
The CRT group had a significantly longer sleep duration than the control group (Fig. 1) . There was no difference in the percentage of time actually asleep, or in the duration of the sleep bouts ( Table 2 ). The CRT group showed less fragmentation (intradaily variability) and a greater amplitude of sleep -wake rhythm than the control group. The subjective measures showed the CRT group to be less flexible in the timing of sleep. The single-item level of the PSQI indicated that none of the individuals in the CRT group was likely to suffer from clearly defined sleep disorders such as narcolepsy, obstructive sleep apnoea syndrome, restless legs or periodic leg movements during sleep, or from a delayed or advanced sleep-phase syndrome. The PSQI also indicated that the CRT group had a significantly earlier habitual bedtime and a slightly but non-significantly later habitual rise-time (Table 2) . Table 3 shows the stepwise regression results. The GH peak was negatively associated with relative amplitude and CTI-languidity. Serum PRL was positively associated with CTI-languidity. This was quite marked for two of the three individuals with very high PRL concentrations (46 and 105 mg/l), who showed the second and third highest scores on the CTI-languidity scale, respectively. Serum PRL was negatively associated with CMQ-morningness. This was especially marked for all three individuals with very high PRL concentrations (30, 46 and 105 mg/l), showing the lowest, second lowest and fourth lowest scores on the CMQ-morningness scale, respectively. Serum leptin, as expressed per kg fat mass, was positively associated with CTI-languidity and negatively associated with CTI-flexibility. The dose of radiation was positively associated with sleep bout duration and negatively associated with tolerance for flexibility in the timing of sleep (CTI-flexibility). Age at treatment was negatively associated with CTI-languidity. None of the variables was a significant determinant of the duration of the sleep period, intradaily stability and intradaily variability. Sex, post-treatment interval and chemotherapy did not have predictive value for any of the sleep variables.
In the CRT group, there was a significant negative correlation of the GH peak with leptin/FM (rho ¼ 2 0.46, P , 0.03), but not with PRL. No significant correlation between leptin/FM and PRL was found.
Discussion
The present study shows that high-dose CRT in childhood is associated with objective and subjective changes in sleep -wake rhythm in adulthood. The most prominent change is an increased sleep duration. Moreover, objective circadian variables did not indicate an attenuated sleep-wake rhythm in the CRT group; on the contrary, the rhythms contained less fragmentation and were of greater amplitude than in the control group. In addition, CRT-treated individuals tolerated less flexibility in the timing of their sleep, which appeared to be an independent finding rather than a confounder of the increased sleep duration (Spearman's rho ¼ 2 0.18, P ¼ 0.15). Differences in socioeconomic obligations, for example less social pressure to get up in the morning, cannot account for the increased sleep duration in the CRTtreated group. As mentioned in the Methods section, participants were matched with respect to social environment and employment, therefore the increased sleep duration and decreased flexibility in scheduling sleep are probably attributable to biological rather than socioeconomic factors.
Within the CRT group, stepwise regression analysis indicated associations of sleep and circadian variables with neuroendocrine status. The association was weak for the objective variables, but rather strong for the subjective variables. Regression analyses indicated that the main group finding of the present studythe increased sleep duration in the CRT group -was not significantly related to their GH status. In contrast, individuals in the CRT group with lower GH peaks had larger circadian amplitudes, suggesting uninterrupted sleep. In spite of this, those with lower GH peaks reported most difficulty in overcoming drowsiness (languidity). These results suggest difficulty in obtaining an adequate level of wakefulness, rather than adequate sleep. Increased sleep duration in adults with isolated GH deficiency has been reported, with beneficial effects of GH supplementation on daytime vigour (28) . As GH gives negative feedback to growth hormone-releasing hormone (GHRH) secretion (29) , it is tempting to suggest that a part of our data may be explained by decreased inhibition of GHRH neurons. It has been demonstrated in humans that GHRH promotes sleep (30) , and findings in an animal study suggested the preoptic area to be the site of action of the sleeppromoting effect of GHRH (31) . High prolactin concentrations were also associated with increased difficulty with the transition from sleep to wakefulness, as indicated by both greater languidity and reduced morningness scores -that is, a low preference for getting up and being active in the morning. This finding may be related to increased slow-wave sleep -from which the transition to wakefulness is difficult -during the last hour of sleep. Like GH, pulses of PRL secretion are associated with the occurrence of slow-wave sleep (11) , and in patients with increased PRL concentrations as a result of prolactinoma, the amount of slow-wave sleep is increased, especially at the end of the period of sleep (12) . Additional neuroendocrine factors of potential interest, such as altered diurnal variations in plasma melatonin, cannot be excluded at present, as they were beyond the scope of the present study.
High concentrations of leptin, expressed per kg fat mass, were also associated with difficulties overcoming drowsiness, and furthermore with decreased tolerance for flexibility in the timing of sleep. Leptin shows a circadian rhythm that is negatively correlated with the circadian amplitude in body temperature and has been suggested to play a part in circadian regulation (13) . In rats, the hypothalamic suprachiasmatic nucleus (SCN) has been shown to generate the diurnal variation in serum leptin (32) , whereas exogenous leptin increases slow-wave sleep (33) . A previous study by other investigators demonstrated greater serum leptin concentrations in adults who received CRT in childhood (16) . In accordance with this, we found a negative correlation between GH reserve and serum leptin expressed per kg fat mass (Spearman's rho ¼ 2 0.46, P , 0.03). Although it is uncertain at present whether this is caused by GH deficiency or, rather, by hypothalamic damage per se, the induction of increased serum leptin by lesioning of the SCN in rats supports the latter possibility (33) . The relationship between prior cranial radiotherapy and alterations in sleep -wakefulness regulation is also supported by a clear dose -effect relationship. A higher dose of radiation was associated with longer sleep-bout durations and decreased tolerance for alterations in the timing of sleep. Treatment at young age was associated with increased difficulty in overcoming drowsiness. The post-treatment interval and chemotherapy showed no significant associations with any of the sleep variables studied. These findings support the notion that CRT-induced alterations in hypothalamic -pituitary functioning are related to the dose of radiation and the age at treatment (4) .
The reduced possibility of attaining optimal wakefulness as found in the present study may have implications for the quality of life. Decreased vigilance in survivors of childhood brain cancer interferes with neuropsychological functioning and quality of life (34, 35) . Poor concentration and attention are the most frequent neuropsychological problems in parent reports (36) . In a recent study of long-term neuropsychological and quality-of-life sequelae after childhood CRT, of all the cognitive measures investigated, the attention deficits were most significantly related to young age at treatment and high dose of radiation, and cognitive functioning was the most prominent impairment on the health-related quality-of-life scale (34) . In GH-deficient adults, impaired energy level was the most common complaint in a quality of life assessment (37) .
Treatment of these complaints related to a disturbed sleep-wake rhythm is of clinical relevance. GH supplementation in adults with isolated GH deficiency has been reported to reduce sleep time and increase of daytime vigour (28) , which is in accordance with our stepwise regression results on subjective sleep, suggesting attenuated languidity with GH supplementation. Given the negative correlation of GH and leptin concentrations (38, 39) , and the normalization of increased leptin concentrations by GH treatment in GH-deficient individuals (40) , it would be of interest to re-evaluate the sleep-wake patterns of individuals receiving GH supplementation.
